Expanded activity and utility of the new fluoroquinolones: a review (Q33544588)

27 July 2017

1 reference

title

Expanded activity and utility of the new fluoroquinolones: a review (English)

1 reference

27 July 2017

Blondeau JM

1

1 reference

27 July 2017

1 January 1999

1 reference

27 July 2017

Clinical Therapeutics

1 reference

27 July 2017

21

1 reference

27 July 2017

1

1 reference

27 July 2017

3-40; discussion 1-2

1 reference

Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability

27 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Antimicrobial-drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Prevention of nosocomial bloodstream infections: a national and international priority.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

DNA Gyrase and the Supercoiling of DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

DNA gyrase: structure and function.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Mechanisms of quinolone resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Mechanisms of resistance to quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Therapeutic advances of new fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Canadian Ciprofloxacin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Canadian Pseudomonas aeruginosa susceptibility study from 48 medical centers: focus on ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Canadian Multicenter Susceptibility Study, with a focus on cephalosporins, from 15 Canadian medical centers. The Canadian Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Genetic profile of a nalidixic acid analog: a model for the mechanism of sister chromatid exchange induction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In vitro activity of OPC-17116

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Neutron and light-scattering studies of DNA gyrase and its complex with DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

The in-vitro susceptibilities of 326 Streptococcus pneumoniae isolates to nine antimicrobial agents including penicillin and newer quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Antibacterial properties of AM-1155, a new 8-methoxy quinolone.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In-vitro activity of trovafloxacin (CP99,219) tested by two methods against 150 vancomycin-resistant enterococcal isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

The chemistry and biological profile of trovafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

1 reference

7 January 2021

Simultaneous resistance to metronidazole, co-amoxiclav, and imipenem in clinical isolate of Bacteroides fragilis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In vitro activities of five quinolones against Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

In-vitro activity of quinolones and macrolides against mycobacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

1 reference

7 January 2021

The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

The clinical pharmacokinetics of levofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Pharmacokinetics and inflammatory fluid penetration of sparfloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Oral bioavailability of trovafloxacin with and without food in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Levofloxacin and sparfloxacin: new quinolone antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Antibiotic dosing--does one size fit all?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

1 reference

7 January 2021

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Quinolones: structure-activity relationships and future predictions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Safety of oral ciprofloxacin. An update based on clinical trial results

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Resistance to ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

The effect of quinolone antibacterials on the gastrointestinal flora compared with that of other antibacterials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Effect of norfloxacin on human oropharyngeal and colonic microflora and multiple-dose pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Theophylline and warfarin interaction studies with grepafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Phase I pilot study of the effects of trovafloxacin (CP-99,219) on the pharmacokinetics of theophylline in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Clinafloxacin-theophylline drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

The clinical relevance of in-vitro resistance to penicillin, ampicillin, amoxycillin and alternative agents, for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Strategies for stemming the tide of antimicrobial resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Resistance issues and treatment implications: pneumococcus, Staphylococcus aureus, and gram-negative rods.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Resistance to antimicrobial drugs--a worldwide calamity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Can antimicrobial activity be sustained? An appraisal of orally administered drugs used for respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Economic impact of oral ciprofloxacin following standard intravenous therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988266-1

7 January 2021

10.1016/S0149-2918(00)88266-1

Identifiers

DOI

1 reference

27 July 2017

1 reference

PubMed ID

10090423